Table 2 Patient and tumour characteristics at recurrence in all cohorts and according to skeletal mass index

Age (years), median (range)

66.0

(36.0–84.0)

74.0

(63.0–79.0)

62.0

(37.0–69.0)

68.0

(43.0–85.0)

72.0

(67.0–77.0)

Sex

Male/female

39 (83.0)/8 (17.0)

2(50)/2(50)

0 (0)/10 (100)

5 ()/24 ()

1 ()/3 ()

Performance status

0/1

37 (78.7)

4 (100)

10 (100)

22 (75.8)

3 (75)

2/3

10 (21.2)

0 (0)

0 (0)

7 (24.2)

1 (25)

NRI*

> 97.5

7 (17.0)

1 (25)

0 (0)

6 (24.0)

0 (0)

97.5–83.5

18 (44.0)

2 (50)

3 (33.4)

8 (32.0)

2 (66.6)

< 83.5

16 (39.0)

1 (25)

6 (66.6)

11 (44.0)

1 (33.4)

Albumin levels (g/L)*

34.0 (18.0–44.5)

34.8 (22.7–40.2)

26.5 (20.2–40.0)

35.0 (18.4–44.5)

35.6 (18.0–39.0)

C-reactive protein**

14.0 (1.0–254.0)

8.5 (3.0–14.0)

26.0 (1.0–199.0)

13.0 (1.0–178.0)

20.5 (3.0–254.0)

BMI (kg/m²)

Median

(min–max)

23.8 (16.4–34.6)

30.3 (26.1–34.6)

24.6 (19.7–29.8)

23.1 (16.4–30.8)

24.9 (21.7–26.6)

Underweight

(< 18.5)

5 (10.6)

0 (0)

0 (0)

5 (17.2)

0 (0)

Normal

(≥ 18.5 < 25.0)

22 (46.8)

0 (0)

6 (60)

14 (48.2)

2 (50)

Overweight

(≥ 25.0 < 30.0)

3 (6.4)

2 (50)

0 (0)

1 (3.4)

0 (0)

Obese (≥ 30.0)

17 (36.2)

2 (50)

4 (40)

9 (31.0)

2 (50)

Special nutritional management***

Oral nutritional supplements

22 (48.9)

1 (25)

5 (55.5)

13 (46.4)

3 (75)

Enteral nutrition

21 (46.7)

3 (75)

3 (33.3)

14 (50)

1 (25)

Parenteral nutrition

2 (4.4)

0 (0)

1 (11.2)

1 (3.7)

0 (0)